The S-1 enables selling stockholders to dump up to 9.7M shares into a thin market ($9M market cap). Combined with 57.95M outstanding warrants deeply out of the money ($0.62 vs $0.27 stock), the overhang is severe. The May 19, 2026 Nasdaq compliance deadline is critical, failure to regain $1 bid price could trigger delisting. Monitor for any reverse stock split announcement or further dilutive financing.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $0.3430entry
- T+1 · 7mo ago +11.66%α +12.00% · $0.3830
- T+5 · 6mo ago +9.33%α +6.98% · $0.3750
- T+20 · 6mo ago +28.86%α +23.60% · $0.4420
- T+60 · 4mo ago −7.67%α −10.74% · $0.3167
How similar events traded
Executive Summary
GT Biopharma filed an S-1 registration statement to register up to 9,723,057 shares of common stock for resale by selling stockholders, consisting of conversion shares, warrant shares, dividend shares, and advisory shares. The company will not receive any proceeds from the sale of these shares. The filing highlights a going concern qualification, Nasdaq non-compliance with the $1 minimum bid price requirement (compliance deadline May 19, 2026), and massive potential dilution from outstanding warrants (57.9M shares at $0.62 weighted average exercise price vs. $0.27 stock price).
Key Facts
- Registers 9,723,057 shares for resale by selling stockholders; company receives no proceeds.
- Going concern qualification from independent auditor (Weinberg & Company) in the 10-K for year ended Dec 31, 2025.
- Nasdaq non-compliance: stock closed below $1 for 30 consecutive days as of Nov 20, 2025; compliance period ends May 19, 2026.
- As of April 15, 2026, 35.6M shares outstanding, with 57.95M additional shares issuable upon exercise of warrants at a weighted average exercise price of $0.62.
- Stock closed at $0.27 on April 29, 2026, well below the $1 minimum bid price requirement.
- Gross proceeds of $9.4 million from Greenshoe Rights exercises used for working capital.
- Series L Preferred Stock carries a 10% annual dividend (12% after May 11, 2026), payable quarterly in cash or stock.
Financial Impact
Massive potential dilution: 57.95M warrant shares at $0.62 exercise price vs. $0.27 stock price, representing ~163% dilution of current 35.6M shares outstanding. Going concern risk with no revenue disclosed.
Risk Factors
- Nasdaq delisting risk if minimum bid price compliance not regained by May 19, 2026.
- Extreme dilution from 57.95M outstanding warrants exercisable at $0.62 vs $0.27 stock price.
- Going concern qualification, cash may not sustain operations through next 12 months.
- Selling stockholders can immediately resell 9.7M shares, creating massive supply overhang.
- No revenue or product revenue disclosed; pre-revenue clinical-stage biotech.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-020697 |
| Exhibit: ex107.htm | 0001493152-26-020697 |
| Exhibit: ex5-1.htm | 0001493152-26-020697 |
| Exhibit: ex23-1.htm | 0001493152-26-020697 |
| Document: 0001493152-26-020697-index-headers.html | 0001493152-26-020697 |
| Document: 0001493152-26-020697-index.html | 0001493152-26-020697 |
| Document: 0001493152-26-020697.txt | 0001493152-26-020697 |
Track record
12 reports on GTBP
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
- Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
- Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
- Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
- Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
- Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
- May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
- Apr 30, 202628w ago S-1 Bearish 7/10 Viewing Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers